{"id":4416,"date":"2025-05-30T18:59:53","date_gmt":"2025-05-31T00:59:53","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=4416"},"modified":"2026-04-01T15:52:29","modified_gmt":"2026-04-01T21:52:29","slug":"baff-april-inhibitors-homing-in-on-igan","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2025\/05\/30\/4416\/baff-april-inhibitors-homing-in-on-igan\/","title":{"rendered":"BAFF \/ APRIL Inhibitors Homing in on IgAN"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Today we discuss the group of BAFF\/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical success has been seen only in IgA nephropathy (IgAN), with an average reduction in proteinuria by half. Alpine Immune Sciences\u2019 povetacicept also had commercial success; it was acquired by Vertex for $4.9 billion in 2024.<\/p>\n\n\n\n

The field of nephrology did not attract much attention by pharma companies for a long time, maybe because so many SLE and lupus nephritis trials failed.  But things are changing.  A better understanding of the pathophysiology of IgAN and MN and the demonstration that BAFF\/APRIL inhibitors can block B-cell activation in a different manner from rituximab is intriguing enough. The fact that these drugs reduce IgA >> IgG levels in blood certainly rekindled interest in conditions related to IgA.  While data convincingly show great improvement in proteinuria, there is still some debate as to whether or not BAFF\/APRIL inhibitors can stop the decline in GFR.  Phase 2 data indeed look promising, and Phase 3 studies are underway for all of these compounds. <\/p>\n\n\n\n

FDA approval hinges on showing improved GFR in patients vs controls, an endpoint that is usually measured at 52 wks.  Reduction in protein- or albuminuria is a surrogate 6-month endpoint that is a more sensitive marker and may serve as preliminary evidence of efficacy.  This is how iptacopan first obtained interim, then full approval.<\/p>\n\n\n\n

Drug development efforts often lead to a better understanding of the diseases under study.  IgAN is certainly better understood now than 10 years ago when the first complement inhibitor and endothelin receptor antagonist trials were initiated.<\/p>\n\n\n\n

IgAN studies are also a lot easier to conduct \u2013 and less risky – than SLE studies.  In IgAN there are objective laboratory endpoints, a situation much more attractive than SLE or RA scores.  Take the history of SLE studies: how many showed a benefit and how long did it take for approval?  We only know of 2 \u2018successes\u2019, belimumab and anifrolumab.  Both had quite a tortuous pathway to approval, and both barely made it.<\/p>\n\n\n\n

The frustrating litany of drug failures in SLE has led to soul-searching by regulators and clinical investigators.  Are we using the right outcome measures to assess drug effects?  Which disease stage is best selected for study?  Are LN patients a more homogeneous group of patients to study? [1]<\/a> <\/p>\n\n\n\n

By contrast, IgAN can claim several recent drug approvals (sparsentan, iptacopan, Nefecon).  The regulatory pathway for companies to follow is straightforward and clear. <\/p>\n\n\n\n

\n

Improvement in proteinuria is a good thing, as it points to normalization of kidney function which should benefit eGFR.  We have not seen a single study in which proteinuria was reduced while GFR worsened<\/p>\n<\/blockquote>\n\n\n\n

\n

As more data accumulates, FDA may make proteinuria, or UPCR, a surrogate endpoint for approval replacing eGFR<\/p>\n<\/blockquote>\n\n\n\n

Still, the exact role of B-cells in IgAN is not totally understood.  Rituximab, a CD20 mAb, failed in a mid-size IgAN PoC trial [3]<\/a>,[2]<\/a>.  However, its MoA is different from that of BAFF\/APRIL inhibitors, which bind to a different receptor (TACI) and \u2013 unlike rituximab – suppress immunoglobulin production in long-lived plasma cells.  Rituximab is not known to reduce IgA levels but BAFF\/APRIL inhibitors (\u201cTACIcepts\u201d) do so consistently, decreasing blood levels by approx. 50%.<\/p>\n\n\n\n

There are 3 \u201cTACIcepts\u201d in development: Atacicept<\/strong>, the grand-daddy of them all; telitacicept, the drug that was approved for SLE in China based on very little Phase 2 data, and povetacicept, the most recent player.\u00a0 All 3 compounds have changed hands a few times, which makes for a rather checkered development history. \u00a0All are essentially similar constructs. We will deal with the purported differences in a later blog.<\/p>\n\n\n\n

Atacicept was first tested in B-cell malignancies (multiple myeloma, B-cell lymphoma), and then in SLE and also in RRMS.  It failed in all these indications.  Almost as an afterthought, it was tested in IgAN as well.  In a Phase 2 study of IgAN, the drug showed clear clinical efficacy reducing proteinuria, hematuria, and IgA levels while preserving GFR.  Great \u2013 but what an Odyssey!  It is now undergoing Phase 3 testing.<\/p>\n\n\n\n

Telitacicept <\/strong>is already approved in China for SLE.  It is now being studied in RA, RRMS,  gMG, NMOSD, Sj\u00f6gren\u2019s and IgAN.  In IgAN patients it produced significant reduction in proteinuria, but information for the other indications is sparse. Publications are often in the form of case reports.  In pSS, results were discordant with only the lower dose being efficacious.  Surprisingly, the only Phase 3 studies active in the US deal are for gMG and SLE. Other indications, including IgAN, are executed in Mainland China [2]<\/a><\/p>\n\n\n\n

For Povetacicept <\/strong>the literature is still quite limited.  Vertex reported an IA of the Phase 1b\/2a RUBY-3 IgAN trial, but many details were not shared.  In this trial 2 doses were being tested, but it remains unclear if there was a dose response; the lower dose was selected for Phase 3.  Povetacicept is under investigation in many other autoimmune diseases as well (MN, LN, ANCA vasculitis, ITP, AIHA, and cold agglutinin disease).<\/p>\n\n\n\n

As is often the case in biology, even when a receptor is successfully identified and blocked by an inhibitor, we are often still uncertain about its clinical use.   Because animal models are so often misleading, companies start a clinical journey of exploration for the right indication.  This leads to a basket trial approach and a series of PoC trials. <\/p>\n\n\n\n

Our insufficient knowledge of disease pathology is at the core of these failures.  In addition, the intertwined pathways in immunology and the redundancy built into the system still present formidable challenges.  We need to get better at this!<\/p>\n\n\n\n

\n

We still have a lot to learn about the origins of IgAN
J. FLOEGE <\/strong>[3]<\/a>,[4]<\/a><\/p>\n\n\n\n

<\/p>\n<\/blockquote>\n\n\n\n

ABBREVIATIONS<\/strong>
APRIL     a proliferation-inducing ligand
ANCA     anti-neutrophil cytoplasmic antibody
BAFF       B-cell activating factor
BLyS       B-lymphocyte stimulator (=BAFF)
GFR        glomerular filtration rate
gMG        generalized myasthenia gravis
IA             interim analysis
IgAN        IgA nephropathy
LN            lupus nephritis
MoA        mode of action
NMOSD neuromyelitis optica spectrum disease
PoC         proof of concept
pSS         primary Sj\u00f6gren\u2019s syndrome
RA           rheumatoid arthritis
RRMS     recurrent multiple sclerosis
SLE         systemic lupus erythematosus
TACI       transmembrane activator, calcium modulator and cyclophilin-ligand interactor
pMN       primary membranous nephropathy
UPCR     urinary protein\/creatinine ratio<\/p>\n\n\n\n

\n\n\n\n

REFERENCES<\/strong>
[1]<\/a> Dolgin E. Lupus in crisis: as failures pile up, clinicians call for new tools.  Nature Biotechnol; 37:7, 2019
[2]<\/a> Clinicaltrials.gov (accessed 5\/29\/25)
[3]<\/a> Floege J.  Glomerular disease: Rituximab therapy for IgA nephropathy Nat Rev Nephrol . 2017 Mar;13(3):138
[4]<\/a> Lafayette R. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2016; 28:1306<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Today we discuss the group of BAFF\/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical success has been seen only in IgA nephropathy (IgAN), with Continue reading BAFF \/ APRIL Inhibitors Homing in on IgAN<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":4421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[2237,1271,2227,2239,2205,2224,2209,2218,2225,2231,2236,2203,2202,2201,2228,2198,5,2234,2214,1583,2211,2212,2200,2238,2221,2222,2215,2216,2217,2213,2235,2210,2229,2219,2241,2207,2206,2232,2220,2233,2223,2208,2230,2242,2240],"class_list":["post-4416","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-aiha","tag-allphase-pharma-consulting","tag-alpine-immune-science","tag-anca-vasculitis","tag-anifrolumab","tag-april","tag-atacicept","tag-b-cell-disorders","tag-baff","tag-benlysta","tag-budesonide","tag-cd19","tag-cd20","tag-cd38","tag-egfr","tag-fabhalta","tag-fda","tag-filspari","tag-gmg","tag-harald-reinhart","tag-iga-nephropathy","tag-igan","tag-iptacopan","tag-itp","tag-ln","tag-lupus-nephritis","tag-membranous-nephropathy","tag-ms","tag-multiple-sclerosis","tag-myasthenia-gravis","tag-nefecon","tag-povetacicept","tag-proteinuria","tag-ra","tag-remegen-biosciences","tag-rituxan","tag-rituximab","tag-saphnelo","tag-sle","tag-sparsentan","tag-taci","tag-telitacicept","tag-upcr","tag-vera-therapeutics","tag-vertex-therapeutics"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-19e","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":5735,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/08\/5735\/comparison-of-baff-april-inhibitors-2\/","url_meta":{"origin":4416,"position":0},"title":"COMPARISON OF BAFF \/ APRIL INHIBITORS \u2013 2","author":"Harald","date":"November 8, 2025","format":false,"excerpt":"Shortly after posting our last blog on tacicepts, new data was published in the NEJM on the pivotal Phase 3 trial of atacicept.\u00a0 This publication by Lafayette et al. provides results from an IA of the ongoing ORIGIN-3 trial.[1] \u00a0We updated our table with this new information that centers on\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5697,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/03\/5697\/comparison-of-baff-april-inhibitors\/","url_meta":{"origin":4416,"position":1},"title":"COMPARISON OF BAFF \/ APRIL INHIBITORS","author":"Harald","date":"November 3, 2025","format":false,"excerpt":"First, a reminder where the name \u2018Berger\u2019s disease\u2019 or Morbus Berger comes from.\u00a0It was Jean Berger, a French pathologist and doctor, who initially identified IgA deposits on the glomeruli of nephritic patients.\u00a0 This was not so long ago; his publication (in French) dates from 1968.[1] Now the race is heating\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":6362,"url":"https:\/\/allphasepharma.com\/dir\/2026\/03\/31\/6362\/igan-therapeutics-the-race-is-on\/","url_meta":{"origin":4416,"position":2},"title":"IgAN Therapeutics – The Race is On","author":"Harald","date":"March 31, 2026","format":false,"excerpt":"Is there a new trend in the journal world: \u00a0publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month 'interim' data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months,\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5771,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","url_meta":{"origin":4416,"position":3},"title":"TACICEPTS VYING FOR YOUR ATTENTION","author":"Harald","date":"November 17, 2025","format":false,"excerpt":"Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the \"Late-Breaking Research\" session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5632,"url":"https:\/\/allphasepharma.com\/dir\/2025\/10\/20\/5632\/telitacicept-in-sle\/","url_meta":{"origin":4416,"position":4},"title":"TELITACICEPT IN SLE","author":"Harald","date":"October 20, 2025","format":false,"excerpt":"In today\u2019s blog we will share our thoughts about a recent NEJM article, entitled \u201cA Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus\u201d.[1] Publications on SLE literally come with a book of abbreviations and definitions nowadays and are not an easy Sunday reads.\u00a0 Of course, there is extensive literature\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/Telitaci-graph-e1760996972139.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":1800,"url":"https:\/\/allphasepharma.com\/dir\/2015\/08\/01\/1800\/qidp-drugs-4th-edition\/","url_meta":{"origin":4416,"position":5},"title":"QIDP Drugs – 4th Edition","author":"Harald","date":"August 1, 2015","format":false,"excerpt":">>> For the latest QIDP list, please click HERE \u00a0<<< Since our\u00a0last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table\u00a0which includes compound, sponsor\u00a0and development stage (Phase). It also indicates whether a drug has been\u00a0the topic of a\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"QIDP 4th edition","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=4416"}],"version-history":[{"count":12,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4416\/revisions"}],"predecessor-version":[{"id":6793,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4416\/revisions\/6793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/4421"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=4416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=4416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=4416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}